Hanna Eriksson

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Elisa A. Rozeman, Alexander M. Menzies, Alexander C. J. van Akkooi et al. · The Lancet Oncology · 2019 · 522 citations

Pharmacy, Oncology, Pharmacokinetics +16

Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma

Kim Thrane, Hanna Eriksson, Jonas Maaskola et al. · Cancer Research · 2018 · 368 citations · Full text

Medicine, Cancer Biology, Oncology +17

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Elisa A. Rozeman, Esmée P. Hoefsmit, Irene L. M. Reijers et al. · Nature Medicine · 2021 · 337 citations · Full text

Medicine, Clinical Sciences, Oncology +16

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials

Judith M. Versluis, Alexander M. Menzies, Karolina Sikorska et al. · Annals of Oncology · 2023 · 123 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Tumour suppressor p16^INK4a – anoikis‐favouring decrease in <scp>N</scp>/<scp>O</scp>‐glycan/cell surface sialylation by down‐regulation of enzymes in sialic acid biosynthesis in tandem in a pancreatic carcinoma model

Maho Amano, Hanna Eriksson, Joachim C. Manning et al. · FEBS Journal · 2012 · 111 citations · Full text

Life Sciences, Biochemistry, Oncology +17